{"product_id":"azenta-pestle-analysis","title":"Azenta PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic cycles, and rapid biotech innovation are shaping Azenta’s strategic outlook in our concise PESTLE snapshot—perfect for investors and strategists who need quick, actionable context; purchase the full PESTLE to access detailed risks, opportunities, and ready-to-use recommendations for immediate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Research Funding Levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAzenta remains highly sensitive to NIH and equivalent agency budgets; US federal bio R\u0026amp;D funding rose to about $58.7B in FY2025 with NIH at roughly $49B, while EU and Japan increased life‑sciences allocations by mid-single digits, sustaining capital investments in automated storage and genomics; these public funding trends directly bolster purchasing by academic and non‑profit labs that are core Azenta customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US-China trade tensions continue to affect supply chains for specialized lab components and genomic data flows; tariffs and export controls since 2022 have contributed to component cost increases of roughly 6–12% for biotech suppliers, affecting Azenta’s margins. Azenta must comply with evolving export controls (eg, US Entity List expansions) that can restrict market access in parts of China and limit cross-border data transfers. Strategic placement of service centers in neutral jurisdictions — reflected in recent investments of $50–120M by industry peers in 2023–2025 — is politically necessary to ensure uninterrupted global service delivery and mitigate regional regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Policy and Reform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegislative shifts on drug pricing and reimbursement in the US and EU—e.g., proposed US Medicare negotiation impacting drugs worth over $150bn in 2024—pressure pharma R\u0026amp;D budgets, affecting Azenta's client spend. Political moves to lower medicine costs often push clients to either reduce internal R\u0026amp;D or outsource to efficiency-focused partners; Azenta saw outsourcing demand rise ~8% in 2024. The company actively tracks these policy changes to tailor services and pricing to client fiscal constraints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology Regulatory Frameworks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical moves to streamline or tighten gene-editing and personalized medicine regulation shape global genomic research volumes; supportive frameworks adopted by 28 countries by late 2025 increased national biotech investments, with OECD reporting a 12% CAGR in public biotech R\u0026amp;D from 2020–2025.\u003c\/p\u003e\n\u003cp\u003eAzenta benefits as these policies boost demand for long-term biobanking and sample management—company revenue from sample management and storage services grew about 18% YoY in 2024, reflecting increased longitudinal study needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28 countries with supportive biotech frameworks by late 2025\u003c\/li\u003e\n\u003cli\u003eOECD: 12% CAGR public biotech R\u0026amp;D (2020–2025)\u003c\/li\u003e\n\u003cli\u003eAzenta sample storage revenue +18% YoY in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-Private Partnership Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments are increasingly funding public-private partnerships to accelerate therapeutics; Azenta supplies technical infrastructure for national biobanking programs, supporting projects like the UK Biobank (over 500,000 samples) and US NIH initiatives that allocated $1.2B+ for genomic infrastructure in 2022–2024.\u003c\/p\u003e\n\u003cp\u003eThese collaborations yield multi-year contracts—Azenta reported \u0026gt;20% of 2024 revenue tied to government or consortium projects—providing predictable cash flow and validating its role in national research infrastructure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAzenta enables large-scale biobanks (hundreds of thousands of samples)\u003c\/li\u003e\n\u003cli\u003eGovernment grants and initiatives funneled $1B+ into genomic\/biobank infrastructure (2022–2024)\u003c\/li\u003e\n\u003cli\u003ePublic contracts accounted for over 20% of Azenta 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAzenta: Strong public-R\u0026amp;D tailwinds and 18% sample-storage growth amid cost pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAzenta is exposed to public R\u0026amp;D budgets (US federal bio R\u0026amp;D ~$58.7B FY2025; NIH ~$49B) and trade\/export controls raising component costs ~6–12%, while supportive biotech regulation in 28 countries and OECD 12% CAGR (2020–2025) boost demand—sample storage revenue +18% YoY 2024; \u0026gt;20% 2024 revenue from public contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS bio R\u0026amp;D FY2025\u003c\/td\u003e\n\u003ctd\u003e$58.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH FY2025\u003c\/td\u003e\n\u003ctd\u003e$49B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent cost rise\u003c\/td\u003e\n\u003ctd\u003e6–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries with supportive frameworks\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD public biotech R\u0026amp;D CAGR (2020–2025)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAzenta sample storage rev growth 2024\u003c\/td\u003e\n\u003ctd\u003e+18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic\/contracts share of 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Azenta across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and forward-looking insights to help executives, consultants, and entrepreneurs identify threats, opportunities, and strategy-ready recommendations for reports, pitch decks, and scenario planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clean, summarized PESTLE of Azenta for quick referencing in meetings or presentations, organized by category for instant clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Capital Market Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech capital markets improved as venture funding for US life sciences rose to $22.3B in 2024 and 2025 saw continued inflows after interest-rate stabilization, boosting demand for Azenta’s outsourced genomic services from cash-constrained small and mid-sized biotechs.\u003c\/p\u003e\n\u003cp\u003eIPO activity recovered, with biotech IPO proceeds reaching $6.1B in 2024, supporting balance-sheet strengthening among core customers and higher outsourcing budgets for R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eHowever, these clients remain sensitive to credit tightening and market volatility; a 10% drawdown in biotech indices historically correlates with a 6–12% cut in early-stage R\u0026amp;D spend, posing downside risk to Azenta revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation in labor and raw materials—global producer price index up 6.5% YoY in 2024—has compressed Azenta’s margins as specialized components and cold-storage energy costs rose ~8–12% annually, forcing margin-sensitive product lines to absorb higher input expenses.\u003c\/p\u003e\n\u003cp\u003eAzenta responded with targeted price increases averaging 3–5% in 2024 and efficiency drives (automation, consolidated logistics) aimed at trimming SG\u0026amp;A and COGS by an expected 150–200 bps over 2024–2025.\u003c\/p\u003e\n\u003cp\u003eExecutive focus remains on calibrating competitive pricing to preserve market share while recovering costs, with management forecasting break-even elasticity thresholds per product line and monitoring raw material spot prices weekly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical R\u0026amp;D Outsourcing Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor pharma outsourced 30-40% more non-core lab services 2021-2024, driving a market for sample management and sequencing projected to reach ~$45B by 2026; Azenta’s 2024 services revenue growth ~22% and recurring-service mix positions it to capture this shift from fixed-cost internal labs to variable-cost external models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a global company with sizable Europe and Asia operations, Azenta faces currency exchange rate volatility that can materially affect reported earnings; in 2024 FX headwinds trimmed about 2–4% off consolidated revenue growth according to company filings.\u003c\/p\u003e\n\u003cp\u003eEconomic instability in key markets can produce adverse currency translations despite strong local performance, with EUR\/USD and USD\/CNY swings of 5–10% in 2023–2024 notably impacting margins.\u003c\/p\u003e\n\u003cp\u003eAzenta uses hedging programs and localized cost structures—over 30% of operating expenses denominated locally—to reduce translation risk and stabilize consolidated financial results.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX headwind reduced 2024 revenue growth ~2–4%\u003c\/li\u003e\n\u003cli\u003eEUR\/USD and USD\/CNY volatility 5–10% (2023–2024)\u003c\/li\u003e\n\u003cli\u003eHedging + \u0026gt;30% costs localized to mitigate translation impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics in STEM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe competition for skilled genomics, bioinformatics, and automation engineers raises labor costs in hubs like Boston and San Francisco, where median biotech salaries rose ~8% in 2024 to $150k–$180k for senior roles, increasing Azenta's operating expenses.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 a specialized talent shortage significantly impacts recruitment and retention, forcing Azenta to allocate more to compensation and hiring, with industry vacancy rates for life-science R\u0026amp;D roles near 12%.\u003c\/p\u003e\n\u003cp\u003eAzenta must invest heavily in automation and digital tools—capital expenditures on lab automation climbed ~15% industry-wide in 2024—to augment headcount and preserve productivity amid the tight labor market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabor-driven wage inflation: senior STEM pay +8% (2024)\u003c\/li\u003e\n\u003cli\u003eTalent shortage: life-science R\u0026amp;D vacancy ~12% (late 2025)\u003c\/li\u003e\n\u003cli\u003eCapEx shift: lab automation spending +15% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAzenta buoyed by biotech funding and IPOs but margins pressured by costs, FX\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImproved biotech funding ($22.3B VC 2024), stronger IPOs ($6.1B 2024) boost Azenta demand, but R\u0026amp;D spend cuts (-6–12% per 10% biotech index drop) and input inflation (PPI +6.5% 2024; cold-storage costs +8–12%) press margins; Azenta raised prices 3–5% and targets 150–200bps efficiency gains while FX headwinds trimmed ~2–4% revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC funding\u003c\/td\u003e\n\u003ctd\u003e$22.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech IPOs\u003c\/td\u003e\n\u003ctd\u003e$6.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePPI\u003c\/td\u003e\n\u003ctd\u003e+6.5% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-storage costs\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice increases\u003c\/td\u003e\n\u003ctd\u003e+3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficiency target\u003c\/td\u003e\n\u003ctd\u003e150–200bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX headwind\u003c\/td\u003e\n\u003ctd\u003e−2–4% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAzenta PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Azenta PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751627665785,"sku":"azenta-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/azenta-pestle-analysis.png?v=1772233578","url":"https:\/\/matrixbcg.com\/products\/azenta-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}